Recently, Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical) received the acceptance notices for two API varieties, dapagliflozin and vonoprazan fumarate, issued by the Center for Drug Evaluation of the National Medical Products Administration, and successfully obtained the registration numbers.
Learn More
On June 21, 2024, Xiangyang Municipal Administration for Market Regulation announced the list of "Xiangyang 2022-2023 'Contract-Abiding and Credit-Worthy Enterprises'". Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical) was successfully awarded this title by virtue of its good social credit and standardized contract management system.
Learn MoreRecently, the clinical trial application for a Class 1 new drug (capsule) developed by Tianshu Pharmaceutical's CDMO partner with its assistance was officially accepted by CDE.
Learn More
Recently, the China Electronics and Information Industry Federation announced the list of the first batch of units that obtained the DCMM Data Management Capability Maturity Certificate in 2024. Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical) was awarded the DCMM Party A Managed Level (Level 2) certification, marking that Tianshu Pharmaceutical's data management capability has met national standards and that it has strong competitiveness and representativeness in data management and operation execution.
Learn MoreRecently, the Phase I construction project of Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical) successfully passed the completion acceptance for safety, completion environmental protection, and occupational disease hazard control effect, marking that Tianshu Pharmaceutical has entered the official production stage.
Learn MoreRecently, the Hubei Provincial Department of Economy and Information Technology announced the third batch of special projects for provincial high-quality manufacturing development in 2023, and Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical) was successfully selected into the list.
Learn More